Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. - Wikidata - awgldk - TriplyDB

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

http://www.wikidata.org/entity/Q33377921

about

Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins Whither or wither microbicides?Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120 A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans.Polyanions--a lost chance in the fight against HIV and other virus diseases?Enhancement of HIV infection by cellulose sulfate.A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats.Surrogacy in antiviral drug development.Hybridization-based detection of Helicobacter pylori at human body temperature using advanced locked nucleic acid (LNA) probes.Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens.Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Antiviral therapy for human immunodeficiency virus infections HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation.Recent advances in anti-HIV natural products.Polymeric anti-HIV therapeutics.Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds.Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models.Sulfated fibroin, a novel sulfated peptide derived from silk, inhibits human immunodeficiency virus replication in vitro.Inducing single-cell suspension of BTI-TN5B1-4 insect cells: II. The effect of sulfated polyanions on baculovirus infection.FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes.Pharmacologic considerations for antiviral drug development.Low molecular weight dextran sulfate binds to human myoblasts and improves their survival after transplantation in mice.The metabolic fate of the Anti-HIV active drug carrier succinylated human serum albumin after intravenous administration in rats.Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models.Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation.Traditional medicines, HIV, and related infections: workshop 2C.Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS.Macromolecular (pro)drugs in antiviral research

P2860

Q27004059-F63FA493-8483-4AB9-BC71-2D3C330F9CA2 Q28369377-6B270DD3-0A28-4D0C-8511-87777DDBC3D0 Q33715907-F58248B1-B621-48FF-901B-E7DD76CF3C9C Q33797964-8FD000D5-AC43-43D0-AC86-063185CD862F Q33889449-4A5DF6D1-746A-4414-B253-DD8CEC84417B Q33907686-7D97CD2E-5803-4FF1-898E-53DCB7877F2F Q34009817-3CD48734-BAD8-4084-9FA7-134AD49C5251 Q34080823-B737A706-5874-45B1-B655-C11CE827684D Q34293761-1D54DA36-DCDC-4CCB-9C62-36C1D4AA4631 Q34722747-E2AA6BF0-14D8-4645-8FE1-FA42C8F214C4 Q35053931-C33B965A-CAA1-4A09-8A0D-39A26C2B2BBF Q35122064-EB0C085A-DE24-4AEF-AAAB-CD9DAEA1ED84 Q35123273-C16049F8-DEDC-421D-9337-A06168F00C7C Q35139547-619D16D8-CC58-485B-9526-C2BA3FEFC97A Q35175233-A236C3BE-EC1C-4115-A8FC-D71542917BEF Q35325810-B993BCCF-DA97-45CD-B6D7-0EED2806E548 Q35366050-3D164717-9304-4BA8-A3FF-666FC5F31677 Q35612098-15B42203-457A-408A-972E-89DFFFF6077E Q36052460-FD2B3282-2D6E-4DA4-AA33-79B8A31A7F2D Q36181360-4A7307B8-5E17-4F88-9FFE-9CD49AFB7DA1 Q37088591-E6127C8E-A44E-4534-BEA0-C4762A1224DC Q37201370-617AC77E-63B4-475A-B529-983A69416588 Q37278750-4B2D8D00-D2BB-43E8-858F-BB53F471C7B2 Q37803138-B6157274-3E2B-4E40-9B4D-BB7FC0E9C4DC Q38245819-A9891BC5-4ECD-400B-94BD-061761BDC4BD Q39248702-AE72195A-D36B-4C0C-80BD-B508C32EA36A Q39885075-C08A9F51-B7D1-4669-ADBC-B3832B938C96 Q40826284-36DD9192-E7F7-42AE-AA9B-CD942428DF64 Q40854583-04E0EE8F-3AA3-4F88-B0E7-B7BB4FB08594 Q41110816-8F684843-CD66-4FE7-AEEF-8595D1277996 Q41119643-92C62D5B-79F6-4E53-AE6C-23E6EFE1547E Q41172065-67505CEC-A728-41C3-AD64-D622E9022734 Q43419500-57AD5AE0-EE05-4BFD-9F77-E1A5271E7853 Q43791104-DBDBD48E-3C5B-4BB7-A974-E88174214F67 Q44852485-D6F0972A-BEC1-426E-9FED-F4CD40012283 Q46903624-CF490D26-729B-46EC-A27C-2FE8B2F1947E Q47310550-CD31C71D-4113-4FC5-BFA7-BA3CCBD5E04B Q47340027-46D61453-E4E6-464B-BF79-8BA315477D5F Q57376798-F0097621-0FA0-4381-BE25-2A2D6B0E7CE7

P2860

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

http://www.wikidata.org/entity/Q33377921

description

1991 nî lūn-bûn

@nan

1991 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@ast

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@en

type

label

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@ast

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@en

prefLabel

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@ast

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@en

P1433

Q33377921-827C94A6-5996-4AFF-AF6C-A93C79CEE93B

P1476

Q33377921-3AE09DEB-DA99-48A9-A5E2-ED50BBD69E4F

P2093

Q33377921-1B09A71D-5499-46DC-A98B-8D472B59FE78

Q33377921-223E9A9C-2063-49F3-8046-F6A6DBA0E46D

Q33377921-34D5FA90-1219-4408-AE76-46ECB880FC72

Q33377921-37725E5F-5DC9-4E0D-84C6-E0B6F79DFE89

Q33377921-5235F0A2-7CB7-497C-ADED-25EF5624C198

Q33377921-5C3C51CD-4E58-44CD-9FEA-3141669D8E72

Q33377921-6CC5A631-76D9-4779-B169-CE71DFAAF487

Q33377921-78781F1E-A682-4465-9FFD-B36C8367C434

Q33377921-8F2D66C3-09D6-470C-9D7D-C3A9D1AC41EF

Q33377921-AF7B5503-6247-4DB3-AC2E-A2E1CC4CF385

P2860

Q33377921-01583815-1924-4D85-A947-E57657AD664D

Q33377921-031BAC64-6883-40A3-B9B3-26D95E7931A9

Q33377921-0DF263EF-47C9-4E48-AC3B-A0FE2451A0F8

Q33377921-18AFD950-5A7F-4C7D-A6F0-0969DF32DECB

Q33377921-1A883F52-C32C-46B7-BF33-EF1BC92F1BA6

Q33377921-30292AB9-A6D8-4ABB-B064-3BD101EDAB5A

Q33377921-4400EAB5-39F8-413A-9BF7-63CD06BF91DA

Q33377921-513E58E9-1051-4174-AC0A-0DA1EB79E422

Q33377921-83850C37-8F26-4704-B6C1-B8F681D7506D

Q33377921-85C761B7-7573-4D33-92CD-18ABB9579FCD

P304

Q33377921-8E3209A9-F41F-4288-9DD0-87F805F1F9FA

P31

Q33377921-A4482478-9D84-4BF7-8A35-B25A047CCE3E

P356

Q33377921-A9AA3B59-3405-4DD5-A5D6-2A6DE7FC490B

P407

Q33377921-46CF3130-86AE-4214-9066-20EBA33AC44C

P433

Q33377921-FD4B547B-4D50-470D-B102-7E31C87265B8

P478

Q33377921-DA4EA417-DFDD-4484-841B-BD51BA00BE2B

P577

Q33377921-8EE45935-628B-4804-8829-31528240E8A6

P698

Q33377921-CA189C54-1565-4199-A5E8-9DA43CE4A125

P932

Q33377921-6C5A26F1-EEFA-4634-AEBB-902A0F21222A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.

@en

P2093

B G Petty

http://www.w3.org/2001/XMLSchema#string

C Flexner

http://www.w3.org/2001/XMLSchema#string

C W Hendrix

http://www.w3.org/2001/XMLSchema#string

D M Kornhauser

http://www.w3.org/2001/XMLSchema#string

H Farzadegan

http://www.w3.org/2001/XMLSchema#string

K J Lorentsen

http://www.w3.org/2001/XMLSchema#string

K M Bell

http://www.w3.org/2001/XMLSchema#string

L J Nerhood

http://www.w3.org/2001/XMLSchema#string

P A Barditch-Crovo

http://www.w3.org/2001/XMLSchema#string

R E Chaisson

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome

Immunomodulating activity of heparin.

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus

Drug reactions. 23. Drug induced alopecia.

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.

P304

2544-2550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.35.12.2544

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

1991-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1810188

http://www.w3.org/2001/XMLSchema#string

P932

245428

http://www.w3.org/2001/XMLSchema#string